Hind Bouzid

Hind Bouzid, PhD, currently serves as Scientist II at Jasper Therapeutics since August 2022. Prior experience includes a Postdoctoral Research Fellow role at Stanford University School of Medicine focused on the effects of Clonal Hematopoiesis of Indeterminate Potential on aging from December 2018 to July 2022, and at Dana-Farber Cancer Institute, where gene therapy approaches for Alzheimer’s disease and ALS were developed from March 2018 to November 2018. A PhD in Hematology/Oncology was obtained from Université Sorbonne Paris Cité, where research on mechanisms leading to Acute Myeloid Leukemia was conducted. Additional educational pursuits include training in Drug Discovery and Entrepreneurship at esteemed institutions such as the University of California, San Francisco, and Stanford University. Hind Bouzid possesses extensive expertise in hematopoietic stem cells, cell culture, genetic modification techniques, and various analytical methodologies.